Biogen Inc vs Docusign Inc — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while Docusign Inc trades at $58.39 (market cap $11.33B). The key difference: Biogen Inc is far larger — about 2.7× Docusign Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | DOCU | |
|---|---|---|
Market Cap | $30.13B | $11.33B |
Sector | Health | Technology |
52-Week High | $216.63 | $85.01 |
52-Week Low | $128.93 | $41.75 |
Enterprise Value | $37.20B | $10.70B |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →